[go: up one dir, main page]

AU2003270166A8 - Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression - Google Patents

Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression

Info

Publication number
AU2003270166A8
AU2003270166A8 AU2003270166A AU2003270166A AU2003270166A8 AU 2003270166 A8 AU2003270166 A8 AU 2003270166A8 AU 2003270166 A AU2003270166 A AU 2003270166A AU 2003270166 A AU2003270166 A AU 2003270166A AU 2003270166 A8 AU2003270166 A8 AU 2003270166A8
Authority
AU
Australia
Prior art keywords
mglu receptors
depression
disorders associated
treating disorders
mglu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003270166A
Other versions
AU2003270166A1 (en
Inventor
Paul Kenny
Athina Markou
Svetlana Semenova
Neil Paterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Scripps Research Institute
Original Assignee
Novartis AG
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Scripps Research Institute filed Critical Novartis AG
Publication of AU2003270166A8 publication Critical patent/AU2003270166A8/en
Publication of AU2003270166A1 publication Critical patent/AU2003270166A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods are provided for treating disorders associated with mGlu receptors by simultaneously inhibiting at least two mGluRs belonging to at least two different groups. In one embodiment, there are provided methods for treating a disorder associated with mGlu receptors 2, 3, and 5, including administering to a subject in need thereof an effective amount of at least one antagonist which modulates mGluR2, mGluR3, and mGluR5. The disorders treated by the method include, for example, nicotine addiction, cocaine addiction, and depression.
AU2003270166A 2002-09-10 2003-09-10 Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression Abandoned AU2003270166A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40986702P 2002-09-10 2002-09-10
US60/409,867 2002-09-10
PCT/EP2003/010061 WO2004024150A2 (en) 2002-09-10 2003-09-10 Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression

Publications (2)

Publication Number Publication Date
AU2003270166A8 true AU2003270166A8 (en) 2004-04-30
AU2003270166A1 AU2003270166A1 (en) 2004-04-30

Family

ID=31994019

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003270166A Abandoned AU2003270166A1 (en) 2002-09-10 2003-09-10 Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression

Country Status (10)

Country Link
US (2) US8354447B2 (en)
EP (1) EP1539149B1 (en)
JP (3) JP2006501265A (en)
CN (2) CN1694701A (en)
AT (1) ATE539768T1 (en)
AU (1) AU2003270166A1 (en)
BR (1) BR0314192A (en)
CA (1) CA2498022C (en)
ES (1) ES2381664T3 (en)
WO (1) WO2004024150A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (en) 2001-06-25 2003-11-11 Niconovum Ab Device for administering a substance to the front of an individual's oral cavity
ATE359075T1 (en) 2002-12-20 2007-05-15 Niconovum Ab CHEMICALLY AND PHYSICALLY STABLE PARTICLE MATERIAL CONTAINING NICOTINE AND MICROCRYSTALLINE CELLULOSE
TWI417095B (en) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CN101848893B (en) 2007-09-14 2012-06-06 奥梅-杨森制药有限公司 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
EP2203439B1 (en) 2007-09-14 2011-01-26 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
AU2008297877C1 (en) 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
CN101861316B (en) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of the MGLUR2 receptor
MX2011002042A (en) 2008-09-02 2011-06-20 Ortho Mcneil Janssen Pharm 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors.
ES2466341T3 (en) 2008-10-16 2014-06-10 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
JP5707390B2 (en) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2430022B1 (en) 2009-05-12 2013-11-20 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US8685404B2 (en) * 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors.
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ME03518B (en) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv COMBINATIONS INCLUDING POSITIVE ALOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR APPLICATIONS
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
AU2018310881C1 (en) 2017-07-31 2021-12-16 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN110151184A (en) * 2019-04-19 2019-08-23 昆明依利科特科技有限公司 Contactless drug addict's rapid detection system and method
CA3203607A1 (en) * 2020-12-11 2022-06-16 Novartis Ag Use of mglur5 antagonists for treating amphetamine addiction
CN114088427A (en) * 2021-11-22 2022-02-25 昆明理工大学 Performance test bench and test method for inerter/suspension

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020259A2 (en) * 1999-10-15 2004-04-30 Hoffmann La Roche Benzodiazepine derivatives
GB0005700D0 (en) 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
US6916821B2 (en) * 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists

Also Published As

Publication number Publication date
WO2004024150A2 (en) 2004-03-25
US20130210849A1 (en) 2013-08-15
US8354447B2 (en) 2013-01-15
CN1694701A (en) 2005-11-09
ES2381664T3 (en) 2012-05-30
JP2010174039A (en) 2010-08-12
AU2003270166A1 (en) 2004-04-30
BR0314192A (en) 2005-07-26
EP1539149A2 (en) 2005-06-15
EP1539149B1 (en) 2012-01-04
WO2004024150A3 (en) 2004-08-19
JP2006501265A (en) 2006-01-12
CA2498022A1 (en) 2004-03-25
JP2014074032A (en) 2014-04-24
US20060148835A1 (en) 2006-07-06
CN102793698A (en) 2012-11-28
ATE539768T1 (en) 2012-01-15
CA2498022C (en) 2012-10-23

Similar Documents

Publication Publication Date Title
AU2003270166A8 (en) Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression
FR13C0062I1 (en)
MXPA05002442A (en) Imidazolopyridines and methods of making and using the same.
IL186200A0 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
WO2005077463A3 (en) Ligand for a monoamine receptor or transporter for treating addiction or dependence
DE60039783D1 (en) LFA-1 ANTAGONISTS AND TNF-ALPHA ANTAGONISTS FOR
PL376373A1 (en) Selected cgrp antagonists, method for production and use thereof as medicament
IL168056A0 (en) Selected cgrp antagonists, method for production and use thereof as medicament
ATE537826T1 (en) COMPOSITIONS OF R(+)- AND S(-)-PRAMIPEXOLE AND METHOD FOR THEIR USE
WO2005107726A3 (en) Method for the treatment of back pain
PT1135153E (en) USES FOR ANTAGONISTS AND AGNISTS OF EPH RECEPTORS FOR TREATING VASCULAR DISORDERS
DE60321965D1 (en) AMID FUNCTIONAL POLYMERS, COMPOSITIONS AND METHODS
MXPA05002443A (en) Pyrazolopyridines and methods of making and using the same.
TW200613302A (en) Nk1 antagonists
TW200505896A (en) Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
MXPA05002418A (en) Substituted 1,4-pyrazine derivatives.
WO2006016192A3 (en) Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia
MXPA06002025A (en) A pharmaceutical composition for the prevention and treatment of addiction in a mammal.
WO2006041769A3 (en) Methods for the treatment of substance abuse and addiction
WO2005094797A3 (en) Use of ampa-receptor antagonists for treating dementia
WO2007062048A3 (en) Role of proteoglycans in drug dependence
WO2004011018A3 (en) Methods of identifying selective beta-1-adrenergic receptor antagonists
DE602004021395D1 (en) METHOD FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase